Ovid's lead drug shows promis­ing ef­fi­ca­cy sig­nal in Frag­ile X syn­drome study, but op­ti­mal dos­ing reg­i­men is un­clear for path for­ward

Take­da and Lund­beck-part­nered rare neu­ro­log­i­cal dis­or­der com­pa­ny Ovid Ther­a­peu­tics has some en­cour­ag­ing mid-stage da­ta from a Frag­ile X study test­ing its lead drug, but there …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER